Immune System Regulation (ISR) Holding Company
 Holding.png)
ISR said March 19 that it is partnering with TCER to develop a COVID-19 vaccine. Data from animal studies are expected to be ready during the second quarter of 2020, with the goal of starting testing in humans during the last quarter of this year. TCER conducts its research in close collaboration with Hans Grönlund, PhD’s research group Therapeutic Immune Design at the Center for Molecular Medicine at Karolinska Institutet.
ISR said in February it was exploring the potential of developing its Immunolid ISR50 vaccine as a treatment for COVID-19. Immunolid50 is in the final phase of toxicological studies, carried out in collaboration with Innostars in Shanghai, in anticipation of a future IND application allowing for human clinical trials.
ISR said in February it was exploring the potential of developing its Immunolid ISR50 vaccine as a treatment for COVID-19. Immunolid50 is in the final phase of toxicological studies, carried out in collaboration with Innostars in Shanghai, in anticipation of a future IND application allowing for human clinical trials.
Technology:
COVID
Industry:
Vaccine/Drug
Headquarters:
Sweden
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership